# Q1 2025 SALES

Juergen Esser Chief Financial Officer





#### DEMONSTRATING THE RELEVANCE OF OUR HEALTH-FOCUSED PORTFOLIO



Note: all data in like-for-like

#### **BROAD-BASED GROWTH ACROSS GEOGRAPHIES**



**+4.3%**Q12025
LFL sales growth

EUROPE	+2.0%
NORTH AMERICA	+3.7%
CHINA, NORTH ASIA & OCEANIA	+9.9%
LATIN AMERICA	+9.0%
AMEA (REST OF THE WORLD)	+3.3%

#### LEVERAGING PRODUCT SUPERIORITY AND DIFFERENTIATION

# Positive LFL sales growth and volume/mix in all categories







Boosting our key platforms, through investments in product superiority and differentiation across categories







#### OUR DIVERSE CHANNEL FOOTPRINT IS PROVIDING US RESILIENCE

#### **AWAY-FROM-HOME**



High-single-digit sales growth

#### PHARMACIES, HOSPITALS, HOME-CARE & SPECIALIZED CHANNELS



High-single-digit sales growth

#### **E-COMMERCE**




High-single-digit sales growth

Note: all data in like-for-like

## **Q1 SALES BRIDGE**

#### LFL GROWTH PARTIALLY OFFSET BY NEGATIVE SCOPE EFFECT




#### **EUROPE**

#### DELIVERING RESILIENT, VOLUME/MIX-DRIVEN GROWTH


#### **Q1 2025 DEVELOPMENTS**

- Sequential improvement in growth momentum
- Further progress in EDP led by functional products, including High Protein
- Resilient growth in Specialized Nutrition driven by Medical; strong growth in Waters ahead of season

#### **LFL SALES GROWTH BY QUARTER**



Sales	€2.4bn
Like-for-like sales growth	+2.0%
Volume/mix   price	+1.9% / +0.0%




#### **NORTH AMERICA**

#### SOLID GROWTH LED BY A CONTINUED STRONG MOMENTUM IN HIGH PROTEIN

#### **Q1 2025 DEVELOPMENTS**

- Consistent winning momentum in High Protein
- Soft start in Coffee Creamers in a competitive category; temporary service challenges
- Strong start in Medical Nutrition, across portfolio; double-digit sales growth in Waters

#### **LFL SALES GROWTH BY QUARTER**



Sales	€1.6bn
Like-for-like sales growth	+3.7%
Volume-mix / price	+0.9% / +2.8%



## **CHINA, NORTH ASIA & OCEANIA**

#### VERY STRONG START TO THE YEAR IN ALL CATEGORIES

#### **Q1 2025 DEVELOPMENTS**

- Consistent market share gains in IMF, with Essensis as a key driver; continued strong demand for Medical
- Double-digit growth in Mizone, in a dynamic category
- Another strong quarter for EDP in Japan with further market share gains

#### **LFL SALES GROWTH BY QUARTER**



Sales	€0.9bn
Like-for-like sales growth	+9.9%
Volume/mix   price	+10.4% / -0.5%




#### **LATIN AMERICA**

#### PRICE-LED GROWTH ACROSS THE REGION

#### **Q1 2025 DEVELOPMENTS**

- Strong growth in Specialized Nutrition led by Aptamil across the region
- Solid growth in EDP led by Danone, Danette & YoPro
- Price-led growth in Waters

#### **LFL SALES GROWTH BY QUARTER**



Sales	€0.7bn
Like-for-like sales growth	+9.0%
Volume/mix   price	-2.1% / +11.1%



## **AMEA (REST OF THE WORLD)**

#### SOLID QUARTER DRIVEN BY EDP AND SPECIALIZED NUTRITION

#### **Q1 2025 DEVELOPMENTS**

- Continued growth in Dairy Africa, led by Morocco
- Solid growth in Specialized Nutrition, notably in India and Middle-East
- Waters impacted by adverse weather conditions

#### **LFL SALES GROWTH BY QUARTER**



Sales	€1.2bn
Like-for-like sales growth	+3.3%
Volume/mix   price	-1.0% / +4.3%



## **2025 GUIDANCE CONFIRMED**

IN LINE WITH MID-TERM AMBITION

LFL sales growth

+3% to +5%

Recurring operating income

Growing faster than sales



## **APPENDIX**





## Q1 2025 SALES BY CATEGORY AND GEOGRAPHY

		EUROPE	NORTH AMERICA	CHINA, NORTH ASIA & OCEANIA	AMEA, CIS & LATIN AMERICA	COMPANY
***************************************	EDP Sales LFL growth	<b>€1,103m</b> +1.5%	<b>€1,459m</b> +2.9%	<b>€95m</b> +8.8%	<b>€725m</b> +8.5%	<b>€3,381m</b> +3.7%
	SPECIALIZED NUTRITION Sales LFL growth	<b>€799m</b> +1.0%	<b>€97m</b> +9.2%	<b>€665m</b> +10.0%	<b>€745m</b> +5.7%	<b>€2,306m</b> +5.3%
0	WATERS Sales LFL growth	<b>€487m</b> +4.7%	<b>€77m</b> +13.1%	<b>€176m</b> +10.2%	<b>€415m</b> -0.2%	<b>€1,156m</b> +4.1%
	COMPANY Sales LFL growth	<b>€2,389m</b> +2.0%	<b>€1,633m</b> +3.7%	<b>€936m</b> +9.9%	<b>€1,885m</b> +5.3%	<b>€6,844m</b> +4.3%

## Q1 2025 SALES BY GEOGRAPHICAL ZONE

	EUROPE	NORTH AMERICA	CHINA, NORTH ASIA & OCEANIA	LATIN AMERICA	REST OF THE WORLD	COMPANY
Q1 sales	€2,389m	€1,633m	€936m	€715m	€1,170m	€6,844m
Like-for-like growth	+2.0%	+3.7%	+9.9%	+9.0%	+3.3%	+4.3%
Volume/mix	+1.9%	+0.9%	+10.4%	-2.1%	-1.0%	+1.9%
Price	+0.0%	+2.8%	-0.5%	+11.1%	+4.3%	+2.4%

## Q1 2025 SALES BY CATEGORY

	***************************************		0	COMPANY
Q1 sales	€3,381m	€2,306m	€1,156m	€6,844m
Like-for-like growth	+3.7%	+5.3%	+4.1%	+4.3%
Volume/mix	+1.5%	+3.1%	+1.0%	+1.9%
Price	+2.2%	+2.3%	+3.1%	+2.4%

## **Q1 2025 SALES BY GEOGRAPHICAL ZONE**

Q1 2025	EUROPE	NORTH AMERICA	CHINA, NORTH ASIA & OCEANIA	LATIN AMERICA	REST OF THE WORLD	TOTAL
Like-for-like sales growth	+2.0%	+3.7%	+9.9%	+9.0%	+3.3%	+4.3%
Scope	-0.3%	-11.3%	-	-	-	-3.0%
Currency and others <sup>1</sup>	+0.6%	+1.7%	+1.6%	-15.1%	-2.0%	-1.0%
IAS 29 impact	-	-	-	-2.3%	-0.7%	-0.4%
Hyperinflation contribution	-	-	-	+6.8%	+1.1%	+0.8%
Reported sales growth	+2.3%	-5.9%	+11.5%	-1.6%	+1.7%	+0.8%

## **CHANGES IN EXCHANGE RATES**

	% total Q1 2025	Q1 25 vs. Q1 24 (avg)
United States Dollar	22.4%	+3.1%
Chinese Renminbi	11.3%	+1.9%
Indonesian Rupiah	5.6%	-1.1%
British Pound	5.5%	+2.5%
Mexican Pesos	4.9%	-14.1%
Polish Zloty	3.1%	+3.2%
<b>Canadian</b> Dollar	2.8%	-3.1%
Argentine Peso	2.5%	-18.4%
항 Brazilian Real	2.4%	-12.8%
<b>C∙</b> T <b>urkish</b> Lira	2.2%	-12.0%
<b>★ Moroccan</b> Dirham	1.9%	+4.4%
<b>Thailand</b> Baht	1.2%	+8.4%

#### **DISCLAIMER**

This presentation contains certain forward-looking statements concerning Danone. In some cases, you can identify these forward-looking statements by forward-looking words, such as "estimate", "expect", "anticipate", "project", "plan", "intend", "objective", "believe", "forecast", "guidance", "outlook", "foresee", "likely", "may", "should", "goal", "target", "might", "will", "could", "predict", "continue", "convinced" and "confident," the negative or plural of these words and other comparable terminology. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.

Although Danone believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a description of these risks and uncertainties, please refer to the "Risk Factor" section of Danone's Universal Registration Document (the current version of which is available on www.danone.com).

Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.

All references in this presentation to Like-for-like (LFL) changes and recurring operating margin correspond to financial indicators not defined in IFRS. Please refer to the financial press releases issued by the Company for further details on IAS29 (Financial reporting in hyperinflationary economies), the definitions and reconciliation with financial statements of financial indicators not defined in IFRS.

Due to rounding, the sum of values presented in this presentation may differ from totals as reported. Such differences are not material.